LEF1 and endometrial cancer: Another candidate that has not yet been evaluated is LEF1, a nuclear effector of the Wnt/beta-catenin pathway [16], overexpressed in CTNNB1-mutated tumours according to the Clinical Proteomic Tumour Analysis Consortium (CPTAC) proteogenomic characterisation of endometrial cancer [17].